Over-methylation locks the aged transcriptome: testing whether intermittent METTL3 inhibition restores synaptic flexibility by rebalancing m6A‑dependent translation and decay

Hypothesis

Intermittent, neuron‑specific reduction of METTL3 activity in aged brains will lower excess m6A on synaptic transcripts, shift the balance toward m6A‑dependent decay, and restore proteostatic flux, thereby rescuing cognitive flexibility without globally suppressing methylation.

Mechanistic Rationale

Normal aging shows elevated m6A in 3′UTRs of synaptic genes, which correlates with increased transcription but reduced turnover [1]. METTL3 drives m6A that enhances FOXO3‑mediated translation while simultaneously inhibiting autophagy, whereas loss of METTL14 stabilizes CAMKK2 mRNA to promote autophagic clearance [2]. We propose that hyper‑methylation creates a "methyl‑ trap": transcripts acquire m6A that recruits YTHDF1/3 for translation, but the same modification overloads YTHDF2‑mediated decay pathways, leading to sequestration of YTHDF2 in stress granules and a net block of mRNA turnover. The result is a static proteome where synthesis outpaces degradation, producing proteostatic gridlock that manifests as synaptic rigidity. Intermittent METTL3 inhibition would transiently decrease m6A load, freeing YTHDF2 to resume decay, allowing autophagy (via FOXO3/CAMKK2) to clear excess proteins and reset the transcriptome.

Testable Predictions

1. Aged mice (≥18 mo) treated with a short‑acting, brain‑penetrant METTL3 inhibitor (e.g., STM2457) given 3 days on/4 days off for 4 weeks will show:
   • A 20‑30 % decrease in m6A peaks at synaptic 3′UTRs measured by MeRIP‑seq.
   • Increased YTHDF2 binding to those transcripts (eCLIP) and reduced YTHDF1/3 occupancy.
   • Elevated autophagic flux (LC3‑II/I ratio, p62 degradation) in hippocampal synaptosomes.
   • Improved performance on reversal learning and novel object recognition tasks.
2. The same regimen in young adult mice (3 mo) will produce no significant behavioral change, indicating an age‑specific window.
3. Genetic rescue: neuronal‑specific overexpression of a catalytically dead METTL3 (dead‑mut) will phenocopy the inhibitor’s effects, confirming on‑target action.
4. Conversely, chronic METTL3 knockdown will exacerbate proteostatic imbalance and accelerate cognitive decline, establishing a dose‑response.

Experimental Approach

• Subjects: Male and female C57BL/6J mice, split into young (3 mo) and aged (18 mo) cohorts.
• Treatment: Oral gavage of STM2457 (10 mg/kg) or vehicle on a 3‑day on/4‑day off cycle for 4 weeks; include a group receiving chronic daily dosing to test toxicity.
• Readouts:
  • MeRIP‑seq and SCARLET for site‑specific m6A quantification.
  • eCLIP for YTHDF1/2/3 binding.
  • Western blot and immunofluorescence for LC3, p62, FOXO3, CAMKK2 in synaptosomal fractions.
  • Behavioral battery: Barnes maze reversal, touch‑screen pattern separation, and in vivo two‑photon imaging of dendritic spine turnover.
  • RNA‑seq to assess transcriptome stability (half‑life via 4sU labeling).
• Controls: Isoform‑specific METTL14 knockdown to verify pathway specificity; autophagy inhibitor (chloroquine) co‑administration to test dependence on flux.

Expected Outcomes and Interpretation

If the hypothesis holds, intermittent METTL3 inhibition will reduce m6A density without abolishing it, shift YTHDF2 from sequestration to active decay, reinstate autophagy‑mediated protein clearance, and improve cognitive flexibility. Lack of effect in young animals would support the notion that the intervention targets an age‑specific over‑methylation state rather than a basal requirement for m6A. Failure to observe changes in m6A or behavior despite drug exposure would falsify the model, suggesting that age‑related rigidity stems from mechanisms independent of m6A‑mediated translational control.

Broader Implications

This work reframes cognitive aging as a reversible state of translational‑decay imbalance driven by excess m6A, offering a precision‑timed epigenetic strategy that avoids global demethylation. Successful validation could inspire clinical trials of short‑interval METTL3 modulators for age‑related cognitive decline, distinct from pro‑plasticity approaches that aim to boost methylation or transcription alone.